Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22077876 | 0.98 | HSD11B1 (0.40) | HSD11B1BTKASGR1KAT8KDM4D | |
| SCHEMBL24622292 | 0.87 | HSD11B1 (0.41) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL4804112 | 0.83 | HSD11B1 (0.40) | HSD11B1ASGR1KAT8KDM4D | |
| SCHEMBL4803692 | 0.83 | HSD11B1 (0.40) | HSD11B1ASGR1KAT8KDM4D | |
| Formic Acid SCHEMBL27813341 | 0.82 | HSD11B1 (0.42) | HSD11B1BTKASGR1KDM4DCHRM2 | |
| SCHEMBL228179 | 0.82 | HSD11B1 (0.46) | HSD11B1BTKASGR1KDM4DCHRM2 | |
| SCHEMBL13943891 | 0.80 | HSD11B1 (0.45) | HSD11B1BTKASGR1KDM4D | |
| SCHEMBL2380370 | 0.80 | HSD11B1 (0.43) | HSD11B1BTKASGR1KAT8KDM4D | |
| SCHEMBL4552317 | 0.79 | HSD11B1 (0.44) | HSD11B1BTKASGR1ADH1CADH1A | |
| SCHEMBL21541517 | 0.78 | HSD11B1 (0.42) | HSD11B1BTKASGR1KAT8KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069884-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | HSD11B1 335/4885BTK 1027/4885ASGR1 2993/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | HSD11B1 3014/4885BTK 2470/4885ASGR1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.